跳至主要内容
临床试验/NCT03860506
NCT03860506已完成1 期

A Double-Blind, Placebo-Controlled, Randomized, Single-Dose, 2-Period Crossover Study of the Pharmacodynamics of Orally Administered PSI-697 in Healthy Subjects Who Smoke

Pfizer0 个研究点目标入组 30 人开始时间: 2008年4月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Pfizer
入组人数
30
主要终点
reduction of platelet monocyte aggregates

研究概览

简要总结

This is a single dose inpatient and outpatient study to test whether an effect on the ability of platelets to stick to white blood cells in subjects who smoke.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Inclusion Criteria:
  • Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12?lead electrocardiogram (ECG).
  • Smoker of at least 1 pack or more of cigarettes per day (20 plus or minus 3 cigarettes) for more than 1 year as determined by history.

排除标准

  • Exclusion Criteria:
  • Any diagnosed bleeding disorder.
  • Any major surgical procedure within 6 months before study day
  • Any history of major bleeding (eg, bleeding peptic ulcer) within 1 year before study day 1.

研究组 & 干预措施

PSI-697

Experimental

干预措施: PSI-697 (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

reduction of platelet monocyte aggregates

时间窗: 2 days

次要结局

未报告次要终点

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

相似试验